Search

Jing Liu

from New York, NY
Age ~34
Get Report
Also known as:
Jin G Liu
Phone and address:
39 Bowery #681, New York, NY 10002
Related to:
Jin Song Liu, 43Siu P Chiu, 60Hsiang Y Chiu, 60Cheungluen ChiuHing W Chiu, 64Shu H Liu, 57Man L Chiu, 59Ming Y Liu, 50
Connected to:
Abraham C Liu, 109Adele T Liu, 65Adi P Liu, 35Alan Y Liu, 39Albert Y Liu, 37Alen K Liu, 39Alma R Liu, 73Amanda T Liu, 54Ambrose M Liu, 53An P Liu, 59

Jing Liu Phones & Addresses

  • 39 Bowery #681, New York, NY 10002
  • Brooklyn, NY
  • Hastings, MN

Professional Records

License Records

Jing Wen Liu

Address:
110 Caton Ave, Brooklyn, NY
Phone:
(718) 552-6782
License #:
83016 - Active
Category:
Health Care
Issued Date:
Aug 8, 2016
Effective Date:
Aug 8, 2016
Expiration Date:
Aug 31, 2017
Type:
Massage Therapist

Medicine Doctors

Jing Liu Photo 1

Dr. Jing Liu, Minneapolis MN - MD (Doctor of Medicine)

View page
Specialties:
Dermatology
Address:
701 Park Ave, Minneapolis, MN 55415
(952) 484-7762 (Phone)

Minneapolis Office
701 Park Ave, Minneapolis, MN 55415
(612) 873-3000 (Phone), (612) 904-4218 (Fax)
Languages:
English
Education:
Medical School
Univ Of Wi Med Sch
Graduated: 2011

Lawyers & Attorneys

Jing Liu Photo 2

Jing Liu

Resumes

Resumes

Jing Liu Photo 3

Jing Liu Minneapolis, MN

View page
Work:
Avago Technology

Mar 2014 to 2000
Analog/mixed signal design engineer
Education:
University of Minnesota-Twin City
Dec 2012
Bachelor of Electrical Engineering
University of Minnesota
Minneapolis, MN
Master of Electrical Engineering in Design

Business Records

Name / Title
Company / Classification
Phones & Addresses
Jing Liu
Principal
So-Il
Architectural Services
68 Jay St, Brooklyn, NY 11201
Jing F. Liu
Managing
Exaclick Limited Liability Company
Prepackaged Software Services
7 E Main St, West Paterson, NJ 07424
PO Box 141, Florham Park, NJ 07932
(908) 432-2838
Jing Liu
Secretary
Home System Group
Jing Liu
Medical Doctor
Jing Liu M.D
Medical Doctor's Office
100 Charles Lindbergh Blvd, Hempstead, NY 11553
(516) 512-5200
Jing Liu
ZE HUAN INC
Nonclassifiable Establishments
42-36 157 St 3, Flushing, NY 11355
4236 157 St 3Fl, Flushing, NY 11355
4236 157 St, Flushing, NY 11355
Jing Huan Liu
NEW ROYAL NAILS SPA INC
Manicures & Pedicures Equipment & Supplies
8918 3 Ave, Brooklyn, NY 11209
(718) 680-4128
Jing Liu
Manager
Trans-Am Air & Sea Freight (Nyc) Inc
Transportation Services · Freight Transportation Arrangement
2016 Linden Blvd, Floral Park, NY 11003
14543 226 St, Jamaica, NY 11413
17717 150 Ave, Jamaica, NY 11434
(718) 656-5800, (718) 525-5800
Jing Fu Liu
Director
LIU'S FAMOUS GRILL INC
17 E Broadway #205, New York, NY 10002
2534 Grn Oaks Rd, Fort Worth, TX 76116

Publications

Isbn (Books And Publications)

Advances in Natural Computation: Second International Conference, ICNC 2006, Xi'an, China, September 24-28, 2006, Proceedings, Part I

View page
Author

Jing Liu

ISBN #

3540459014

Advances in Natural Computation: Second International Conference, ICNC 2006, Xi'an, China, September 24-28, 2006, Proceedings, Part II

View page
Author

Jing Liu

ISBN #

3540459073

Fuzzy Systems and Knowledge Discovery: Third International Conference, FSKD 2006, Xi'an, China, September 24-28, 2006, Proceedings

View page
Author

Jing Liu

ISBN #

3540459162

Us Patents

Ordered Assembly Of Membrane Proteins During Differentiation Of Erythroblasts

View page
US Patent:
20100323393, Dec 23, 2010
Filed:
Jun 22, 2010
Appl. No.:
12/820933
Inventors:
Xiuli An - Bayside NY, US
Mohandas Narla - New York NY, US
Jing Liu - Woodside NY, US
Susanne Heck - Bronx NY, US
International Classification:
C12Q 1/06
C12N 5/078
C12Q 1/02
C12Q 1/04
US Classification:
435 39, 435325, 435 29, 435 34
Abstract:
Disclosed herein are methods for the isolation, identification, and quantification of red blood cells and red blood cell precursors at different developmental stages. Also disclosed are methods for monitoring ex vivo proliferation and differentiation of red blood cells and red blood cell progenitors.

Ordered Assembly Of Membrane Proteins During Differentiation Of Erythroblasts

View page
US Patent:
20120295285, Nov 22, 2012
Filed:
Jul 13, 2012
Appl. No.:
13/548761
Inventors:
Xiuli An - Bayside NY, US
Mohandas Narla - New York NY, US
Jing Liu - Woodside NY, US
Susanne Heck - Bronx NY, US
Assignee:
NEW YORK BLOOD CENTER, INC. - New York NY
International Classification:
C12Q 1/04
G01N 21/64
G01N 33/566
C12Q 1/06
US Classification:
435 725, 435 34, 435 39
Abstract:
Disclosed herein are methods for the isolation, identification, and quantification of red blood cells and red blood cell precursors at different developmental stages. Also disclosed are methods for monitoring ex vivo proliferation and differentiation of red blood cells and red blood cell progenitors.

Methods For High Density Lipoprotein Cholesterol Regulation

View page
US Patent:
20130017250, Jan 17, 2013
Filed:
Jul 16, 2012
Appl. No.:
13/550567
Inventors:
Henry Ginsberg - Dobbs Ferry NY, US
Jing Liu - New York NY, US
Assignee:
The Trustees of Columbia University in the City of New York - New York City NY
International Classification:
A61K 38/44
G01N 21/76
A61P 3/10
C07H 21/04
A61K 9/127
A61P 9/00
G01N 21/17
G01N 21/64
US Classification:
424450, 435 29, 435 8, 424 944, 536 241
Abstract:
It was discovered that insulin binding to insulin receptors signals the upregulation of expression of the liver enzyme deiodinase 1 (Dio1), which in turn activates the ApoA-1 promoter, thereby thereby increasing ApoA-1 expression (primarily in the liver), that in turn raises the levels of plasma ApoA-1, the major and necessary protein in HDLC. Certain embodiments of the invention are directed to methods for increasing circulating HDLC levels in an animal by administering therapeutically effective amounts of Dio1, or by increasing the level of Dio1 through gene therapy.

2-Aminopyrimidine Modulators Of The Histamine H4 Receptor

View page
US Patent:
20130158258, Jun 20, 2013
Filed:
Feb 12, 2013
Appl. No.:
13/765639
Inventors:
Janssen Pharmaceutica NV - New Brunswick NJ, US
Frank CHAVEZ - San Diego CA, US
James P. EDWARDS - San Diego CA, US
Annie E. FITZGERALD - San Diego CA, US
Jing LIU - San Diego CA, US
Neelakandha S. MANI - San Diego CA, US
Michele C. RIZZOLIO - San Diego CA, US
Brad M. SAVALL - San Diego CA, US
Deborah M. SMITH - San Diego CA, US
Jennifer D. VENABLE - Solana Beach CA, US
Jianmei WEI - San Diego CA, US
Danielle K. WIENER - La Jolla CA, US
Ronald L. WOLIN - San Diego CA, US
Assignee:
Janssen Pharmaceutica NV - New Brunswick NJ
International Classification:
C07D 239/48
C07D 471/04
C07D 405/14
C07D 409/14
C07D 487/10
C07D 403/04
US Classification:
540575, 544230, 544295, 544323
Abstract:
2-Aminopyrimidine compounds are described, which are useful as Hreceptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by Hreceptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

2-Aminopyrimidine Modulators Of The Histamine H4 Receptor

View page
US Patent:
20130158259, Jun 20, 2013
Filed:
Feb 13, 2013
Appl. No.:
13/766375
Inventors:
JANSSEN PHARMACEUTICA NV - New Brunswick NJ, US
Frank CHAVEZ - San Diego CA, US
James P. EDWARDS - San Diego CA, US
Annie E. FITZGERALD - San Diego CA, US
Jing LIU - San Diego CA, US
NEELAKANDHA S. MANI - San Diego CA, US
Michele C. RIZZOLIO - San Diego CA, US
Brad M. SAVALL - San Diego CA, US
Deborah M. SMITH - San Diego CA, US
Jennifer D. VENABLE - Solana Beach CA, US
Jianmei WEI - San Diego CA, US
Danielle K. WIENER - La Jolla CA, US
Ronald L. WOLIN - San Diego CA, US
Assignee:
JANSSEN PHARMACEUTICA NV - New Brunswick NJ
International Classification:
C07D 498/04
C07D 401/04
C07D 403/04
C07D 487/04
C07D 487/10
C07D 487/08
C07D 405/04
C07D 405/14
C07D 239/95
C07D 239/70
C07D 239/48
C07D 471/04
US Classification:
540575, 544295, 544323, 544253, 544230, 544105
Abstract:
2-Aminopyrimidine compounds are described, which are useful as Hreceptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by Hreceptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

Wd40 Repeat Domain Protein 5 (Wdr5) Degradation / Disruption Compounds And Methods Of Use

View page
US Patent:
20220348580, Nov 3, 2022
Filed:
Jun 21, 2019
Appl. No.:
17/254345
Inventors:
- New York NY, US
- Chapel Hill NC, US
Jing Liu - New York NY, US
Xufen Yu - New York NY, US
Dongxu Li - Chapel Hill NC, US
International Classification:
C07D 487/04
C07D 401/14
C07D 417/14
Abstract:
Disclosed herein are WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds including a WDR5 ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of WDR5-mediated diseases.

Photo Induced Control Of Protein Destruction

View page
US Patent:
20220288207, Sep 15, 2022
Filed:
Jul 24, 2020
Appl. No.:
17/629707
Inventors:
- Boston MA, US
- New York NY, US
Husnu Umit KANISKAN - New York NY, US
He CHEN - New York NY, US
Jing LIU - Boston MA, US
Assignee:
Beth Israel Deaconess Medical Center, Inc. - Boston MA
Icahn School of Medicine at Mount Sinai - New York NY
International Classification:
A61K 41/00
A61K 47/55
A61K 47/54
A61P 35/00
Abstract:
By hijacking endogenous E3 ligase to degrade protein targets via the ubiquitin-proteasome system, PROTACs (PRoteolysis TArgeting Chimeras) provide a new strategy to inhibit protein targets that were previously regarded as undruggable. The compounds described herein comprise a photolabile group on PROTACs, enabling the degradation of protein targets in a spatiotemporally controlled manner By adding a photolabile caging group on ubiquitin recruiting moieties, light-inducible protein degradation was acheived. These opto-PROTACs display no activity in the dark, while restricted degradation can be induced at a specific time and rate by UVA-irradiation. Accordingly, these compounds provide light-controlled PROTACs and methods of using such compounds.

Protein Tyrosine Kinase 6 (Ptk6) Degradation / Disruption Compounds And Methods Of Use

View page
US Patent:
20230070613, Mar 9, 2023
Filed:
Jul 3, 2019
Appl. No.:
17/256516
Inventors:
- New York NY, US
Hanna Irie - New York NY, US
Jing Liu - New York NY, US
Yan Xiong - New York NY, US
Jessica Byerly - New York NY, US
Shannon Tomita - New York NY, US
Jianping Hu - New York NY, US
International Classification:
A61K 47/54
A61P 35/00
A61K 45/06
Abstract:
Disclosed herein are protein tyrosine kinase 6 (PTK6) degradation/disruption compounds including a PTK6 ligand, a N degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of FTK6-mediated diseases.
Control profile
Jing Liu from New York, NY, age ~34 Get Report